Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.
2.

Optimal sample size determinations from an industry perspective based on the expected value of information.

Willan AR.

Clin Trials. 2008;5(6):587-94. doi: 10.1177/1740774508098413.

PMID:
19029207
3.

Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.

Willan A, Kowgier M.

Clin Trials. 2008;5(4):289-300. doi: 10.1177/1740774508093981.

PMID:
18697843
4.

The value of information and optimal clinical trial design.

Willan AR, Pinto EM.

Stat Med. 2005 Jun 30;24(12):1791-806. Erratum in: Stat Med. 2006 Feb 28;25(4):720.

PMID:
15806619
5.

Implementing a decision-theoretic design in clinical trials: why and how?

Palmer CR, Shahumyan H.

Stat Med. 2007 Nov 30;26(27):4939-57.

PMID:
17582801
6.

Accounting for between-study variation in incremental net benefit in value of information methodology.

Willan AR, Eckermann S.

Health Econ. 2012 Oct;21(10):1183-95. doi: 10.1002/hec.1781.

PMID:
21882285
7.

An investment appraisal approach to clinical trial design.

Backhouse ME.

Health Econ. 1998 Nov;7(7):605-19.

PMID:
9845254
8.
9.

Sample size determination for cost-effectiveness trials.

Willan AR.

Pharmacoeconomics. 2011 Nov;29(11):933-49. doi: 10.2165/11587130-000000000-00000. Review.

PMID:
21988292
10.

Optimal clinical trial design using value of information methods with imperfect implementation.

Willan AR, Eckermann S.

Health Econ. 2010 May;19(5):549-61. doi: 10.1002/hec.1493.

PMID:
19399753
11.
13.

The value of value of information: best informing research design and prioritization using current methods.

Eckermann S, Karnon J, Willan AR.

Pharmacoeconomics. 2010;28(9):699-709. doi: 10.2165/11537370-000000000-00000.

PMID:
20629473
14.

The cost-benefit of a randomized trial to a health care organization.

Hornberger J, Eghtesady P.

Control Clin Trials. 1998 Apr;19(2):198-211. Review.

PMID:
9551284
15.

Value of information analysis optimizing future trial design from a pilot study on catheter securement devices.

Tuffaha HW, Reynolds H, Gordon LG, Rickard CM, Scuffham PA.

Clin Trials. 2014 Dec;11(6):648-56. doi: 10.1177/1740774514545634.

PMID:
25084784
16.

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

Breeze P, Brennan A.

Health Econ. 2015 Nov;24(11):1468-82. doi: 10.1002/hec.3103.

PMID:
25204721
17.

Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.

Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, Harris S.

Clin Trials. 2012 Dec;9(6):671-80. doi: 10.1177/1740774512461859.

PMID:
23250942
19.

Paradigms for adaptive statistical information designs: practical experiences and strategies.

Wang SJ, Hung HM, O'Neill R.

Stat Med. 2012 Nov 10;31(25):3011-23. doi: 10.1002/sim.5410.

PMID:
22927234
20.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd..

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
Items per page

Supplemental Content

Support Center